Video

Dr. Olawaiye on Front Line Treatment Sequencing Considerations in Ovarian Cancer

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

Alexander B. Olawaiye, MD, director, Gynecologic Oncology Research Program, professor, Gynecologic Oncology, Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Women’s Hospital, the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses front line treatment sequencing considerations in ovarian cancer.

The ovarian cancer treatment landscape currently faces the unique problem of having several agents available for treatment in the frontline setting, Olawaiye says. Due to the various treatment choices, it is crucial for clinicians to monitor the latest data when deciding between certain treatments, Olawaiye explains.

Patient costs, including those beyond monetary expenses, need to be factored into treatment decisions for this patient population, Olawaiye continues. Using the data and examining potential toxicities are important steps toward identifying the proper treatment for each patient, Olawiaye concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP